🇺🇸 FDA
Pipeline program

BZD discontinuation protocol

H-38981

Phase 2 small_molecule completed

Quick answer

BZD discontinuation protocol for Substance Use Disorders is a Phase 2 program (small_molecule) at BRIGHT MINDS BIOSCIENCES INC. with 1 ClinicalTrials.gov record(s).

Program details

Company
BRIGHT MINDS BIOSCIENCES INC.
Indication
Substance Use Disorders
Phase
Phase 2
Modality
small_molecule
Status
completed

Clinical trials